ARTICLE | Clinical News
Targretin bexarotene gel regulatory update
February 14, 2000 8:00 AM UTC
The FDA granted priority review status to LGND's NDA, submitted last December, for its Targretin 1 percent gel to treat cutaneous T cell lymphoma (CTCL) (see BioCentury, Dec. 13, 1999). LGND's Targre...